Newsletter Tool

PM Tracker

Today’s Big News

Nov 7, 2024

Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit

Sarepta axes late-phase DMD drug over safety signal, FDA talks

Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales

VC Aditum Bio hatches autoimmune-focused Oblenio Bio with asset from Chinese biotech

AbbVie’s Skyrizi rockets to top of TV drug ad spenders’ list with single largest monthly total this year

Featured

Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit

By Zoey Becker

Gilead's CAR-T therapies Yescarta and Tecartus have stayed relatively flat all year with its Yescarta facing a 1% decline over the third quarter due to competition.

Sarepta axes late-phase DMD drug over safety signal, FDA talks

By Nick Paul Taylor

Sarepta Therapeutics has ended development of a late-phase Duchenne muscular dystrophy (DMD) drug candidate over a safety problem. The safety signal deprived Sarepta of a near-term shot at accelerated approval—and took down the biotech’s entire PPMO franchise.

Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales

By Kevin Dunleavy

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. But the Massachusetts biotech's RSV shot fell way short of expectations.

VC Aditum Bio hatches autoimmune-focused Oblenio Bio with asset from Chinese biotech

By Darren Incorvaia

California VC firm Aditum Bio is reaching across the Pacific to hatch a brand-new biotech. Teaming up with Leads Biolabs, a company based in China, the partners are launching Oblenio Bio to develop a tri-specific T-cell engager antibody for autoimmune diseases.

AbbVie’s Skyrizi rockets to top of TV drug ad spenders’ list with single largest monthly total this year

By Ben Adams

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October.

ADC Therapeutics axes lead solid tumor drug after phase 1 setback, pivots to preclinical programs

By Nick Paul Taylor

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed antibody-drug conjugate after failing to show a favorable benefit-risk profile in a phase 1b trial.

More turbulence at Aurinia as autoimmune drugmaker lays off 45% of workforce

By Angus Liu

After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring, cutting the autoimmune disease biotech's workforce for a second time in less than a year.

Genmab axes 3 programs to focus on plumped-up pivotal pipeline

By Nick Paul Taylor

An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical programs to accelerate investment in its recently expanded phase 3 pipeline.

Fierce podcasts

Don’t miss an episode

Drug pricing and the 2024 presidential election

This week on "The Top Line," we explore how each presidential candidate’s approach to drug pricing could shape future policy.

The pulse of the medtech industry

Best practices for health system-startup partnerships

Resources

Whitepaper

Single Cell RNA Profiling FFPE Tissue

Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence.

7 “Make or Break” Factors for Emerging Biopharma Companies

This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Intensified Biomanufacturing

Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game!

Sponsored by: Syngene International Ltd.

Whitepaper

Is That Heart Attack Really an Adverse Event?

Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results.

Planning for success in cell-based manufacturing

Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes.

Presented by: Thermo Fisher Scientific